arrow
A

Andrew Woodhead

astex pharmaceuticals
H指数:10
被引数:2,031

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2) (vol 67, pg 4655, 2024)

基于片段的SH2结构域蛋白酪氨酸磷酸酶-2(SHP2)别构抑制剂的发现(vol 67, pg 4655, 2024)

2025-05-080
PRE
Integrating fragment-based screening with targeted protein degradation and genetic rescue to explore eIF4E function

整合片段筛选、靶向蛋白降解和遗传拯救以探索eIF4E功能

2024-11-201
OA
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
2024-06-272
PRE
Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)
2024-03-113
PRE
Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
2010-07-28249
PREAI
Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency
2010-07-27176
PREAI
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design
2008-07-26374
PREAI